

# Sterne Kessler Goldstein Fox

Robert Greene, Jr.  
Edward J. Kesseler  
John A. Goldstein  
David X. S. Kim  
Robert W. Linscott  
Hans G. Loeffler  
Michele A. Lombard  
Mark R. Ross  
Robert E. Sauer  
Eric K. Steffey  
Mark H. Lee  
Steven R. Ludwig  
John M. Lustig  
Linda A. Lynch  
Robert T. M. Lytle  
Lawrence B. Budde, Jr.  
Donald J. Featherstone  
Michael J. Messinger

Jeffrey K. Kim  
Matthew J. Shea, Jr.  
Patrick V. Garrett  
Jeffrey J. Heileman  
Hendrik Klaasen  
Troy L. Knapp  
Edward W. Lee  
Albert Lenz,\*  
Donald R. Bartholomew  
Peter A. LaMantia  
Mary A. McCaffrey  
Terence J. Medler  
Jeffrey S. Weeder  
Katherine A. Patterson  
Cynthia A. Paulson  
Albert Fasan, Jr.\*  
Edwina Elusion Floyd  
W. Russel Swindler

Thomas C. Flatau  
Brian C. De Burio  
Sang Lee Beeston  
Richard J. Czajka  
Katherine M. Feltz  
Josephine A. Ward  
Elizabeth A. Martin  
Bruce E. Chalker  
Joseph S. Dittman  
Peter R. Thompson  
Christine M. Mueller  
Ranjith Pramugiaran  
Janet Shasheney,\*  
Joseph L. Lutz,\*  
George S. Bartholomew  
James A. Klein  
Rodney G. Mate  
Eason D. Eisenberg  
Michael A. Specht

Registered Patent Agents:  
Karen R. Markowitz  
Andrea J. Kamage  
Gary J. Dehn  
Anne F. Zimmerman  
Heather S. Johnson  
Gaby C. Longworth  
Matthew J. Dowd  
Aaron J. Schwartz  
Arielle L. Lerner  
Barry A. Matvienko  
Mary B. Tong  
Katherine Peacock  
Brian J. Sexton  
Robert A. Szwartzman  
Jenny A. Quigley  
Timothy A. Doyle  
Jennifer R. Mahan-Matula

Set of Counsel:  
Samuel C. Fox  
Kenneth C. Bass  
John A. Turner  
  
\*Admitted only in Maryland  
\*\*Admitted only in Virginia  
\*\*\*Admitted only in Texas  
\*\*\*\*Practice Limited to  
Federal Agencies



September 24, 2002

WRITER'S DIRECT NUMBER:

(202) 789-5511

INTERNET ADDRESS:

http://uspto.net.uspto.gov

Art Unit 1644

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/065,902; Filed: April 24, 1998  
For: **Purified 20 kDa Presenilin 2 C-Terminal Fragment and Methods of Screening for Compounds that Inhibit Proteolysis of Presenilin 2**  
Inventors: TANZI and KIM  
Our Ref: 0609.4270001/JAG/HLK/PSC

Sir:

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.111; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Heidi L. Kraus  
Attorney for Applicants  
Registration No. 43,730

HLK/PSC/lam

11-29-02  
JAG/JR  
07/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

TANZI and KIM

Appl. No. 09/065,902

Filed: April 24, 1998

For: **Purified 20 kDa Presenilin 2 C-Terminal Fragment and Methods of Screening for Compounds that Inhibit Proteolysis of Presenilin 2**

RECEIVED

Confirmation No.: 8113

Art Unit: 1644

Examiner: Nolan, P.

JAG CENTER 1600-2900

Atty. Docket: 0609.4270001/JAG/HLK/PSC

**Amendment And Reply Under 37 C.F.R. § 1.111**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Office Action dated **June 24, 2002**, (PTO Prosecution File Wrapper Paper No. 28), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R.